RHD and anemia (phenotype): Although IVIg products are approved as safe and effective and meet European standards recommending low levels of anti-A and anti-B haemagglutinins (<1/64), the passive transfer of IgG antibodies against the blood group A, B and RhD antigens has been associated with adverse reactions in recipients, including haemolysis and anaemia in severe cases [7].